ASH 2021

Part I: Pola-R-CHP - possible new standard in 1st line?

Part II: CAR-T cells - all over the field data for DLBCL

axi-cel, tisa-cel, liso-cel: New CAR-T options for R/R DLBCL

Axi-cel - new standard for r/r LBCL patients?

Prevention of CNS relapse after R-CHOP

pola-R-CHP vs. R-CHOP: a new standard?

HD-MTX does not lower SCNS rates in high-risk patients

Tisa-cel - new CAR-T option for R/R aNHL

pola-R-CHP vs. R-CHOP: Neuer Standard?

Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen beim r/r DLBCL

Axi Cel: un nuovo standard nel DLBCL recidivato o refrattario

La prevenzione della recidiva a carico del sistema nervoso Centrale nel DLBCL

Part I: Potential change in first-line treatment?

Part II: The white elephant in the room - BTKi

Encouraging real world safety and efficacy data of brexu-cel in R/R MCL in a population outside of ZUMA-2

Next generation BTKI Pirtobrutinib

Glofitamab SUD as monotherapy after Gpt induced high response rates

Pirtobrutinib shows promising efficacy and safety in heavily pretreated patients with MCL, including those previously treated with BTKi

Low-dose lenalidomide added to rituximab maintenance in older patients with MCL prolongs PFS, but not OS

HiDAC-containing induction before ASCT substantially prolongs TTF and PFS in younger patients with MCL - Final results of the MCL YOUNGER trial

Pirtobrutinib - promising agent moving forward

Focus on maintenance is critical in MCL

Maintenance with Rituximab-Lenalidomid (R2)

La inducción con citarabina a dosis altas antes del transplante autólogo en pacientes jóvenes con LCM prolonga significativamente el TFT y la SLP - Resultados finales del estudio MCL YOUNGER

Pirtobrutinib es eficaz y seguro en pacientes muy pretratados con LCM, incluyendo pacientes que habían fracasado a iBTK

Eficacia y seguridad de brexu-cel en pacientes con LCM r/r de la vida real

Rituximab-Lenalidomid Erhaltungstherapie (R2)

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

Ruolo del mantenimento con R2 nel linfoma mantellare

Añadir lenalidomida a dosis bajas a rituximab en el mantenimiento de pacientes mayores con LCM prolonga la SLP, pero no la SG

Part I: CAR-T cells on the way

Part II: Bi-specific antibodies as an attractive agent

MRD monitoring in follicular lymphoma is extremely valuable

First-line options and RM

Novel immunotherapy approaches to R/R follicular lymphoma

Active new therapy for 3L+ R/R FL

Rituximab-Erhaltung nach ICT bleibt Standard

Mosunetuzumab + Lenalidomid beim r/r FL

Ruolo del monitoraggio della malattia minima residua nel linfoma follicolare

Part I: Promising data in CLL

Part II: More data to wait for

BTKi as new option for untreated CLL/SLL patients

Pirtobrutinib - promising efficacy in heavily pretreated CLL/SLL patients

Big data on smoldering multiple myeloma: the iStopMM trial

NDMM: On the way to cure?

The immunotherapy tsunami continues - bispecific antibodies

The immunotherapy tsunami continues - CAR-T cells

The future is already here - the use of antibodies in newly diagnosed patients

Quadruple regimens for NDMM

Triplet therapie in elderly patients

PFS separation in the Griffin trial

No benefit for elotuzumab in NDMM

Positive results for high-risk myeloma from the UK

Quadruple therapy - the treatment of choice in NDMM

The future is already here - the use of antibodies in newly diagnosed patients

Isatuximab + RVd erfogreich, Elotuzumab nicht

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei NDMM

PFS separation in the Griffin trial

New bispecific antibodies and CAR-T cells for RRMM patients

Personalized medicine with venetoclax

talquetamab & cevostamab: bispecific antibodies beyond BCMA

Is CAR-T cell treatment better in heavly pretreated patients?

TAK-573 - a really new mechanism of treatment in multiple myeloma

KRd consolidation reverses PET positivity in 1/3 of the patients

Not another BCMA drug

Elranatamab - a new bispecific antibody in RRMM

cilta-cel: early, deep and durable responses in heavily pretreated patients

cilta-cel highly effective in heavily pretreated patients

Update on bispecific antibody teclistamab

cilta-cel hoch erfolgreich bei stark vorbehandelten Patienten

TAK-573 - a really new mechanism of treatment in multiple myeloma

KRd consolidation reverses PET-positivity in 1/3 of the patients

New bispecific antibodies and CAR-T cells for RRMM patients

CAR-T oder bispezifische MoAk in der Rezidivtherapie - oder beides?

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen beim r/r MM

Talquetamab und Cevostamab: Neue bispezifische Ak jenseits von BCMA

Bispezifischer Antikörper Teclistamab beim r/r MM

New reference values for light chains in multiple myeloma associated with renal failure

MGUS and COVID-19 risk

Myeloma precursor disease 2021

New reference values for light chains in multiple myeloma associated with renal failure

Myeloma precurser disease 2021

Prävalenz und Risikostratifikation beim SMM